SMi are proud to announce the launch of their inaugural conference on Pharmaceutical Microbiology.

Microbiological contamination of products and processes in a lab and manufacturing environment continues to be a major problem to the Pharmaceutical and Biotechnological industries and its regulators. The potential impact of such contamination can be enormous, and does not only create health and safety problems but can also cost companies millions in lost product revenue.

Put simply, microbial contamination can kill patients and business!

This conference aims to address; the latest developments and procedures used in the identification and prevention of contaminating agents; the design and validation of new lab environments; sterile manufacture and process validation; the challenges facing the Pharmaceutical Microbiology industry; and updates on new rules and regulations.
 

“Contamination of an aseptic process can have a serious impact on a company’s financial viability, manufacturing license and industry reputation. Regulatory GMP codes for the aseptic manufacture of human and veterinary products mandates that an incidence involving product sterility failure or media fill contamination must be fully investigated, and also that the manufacturer establishes an environmental monitoring program that is properly validated to ensure that any environmental contaminates are detected.”

Conference website:
http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3472